FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML

Matsukawa, Toshihiro; Onozawa, Masahiro; Kondo, Takeshi et al.

Annals of hematology, 2024, 103(12), 5333-5340

Permalink : https://hdl.handle.net/2115/97325

このアイテムのアクセス数:54件（2026-07-13 21:00 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
huscap_draft pdf 562 KB 48
Supp Fig1 tif 1.85 MB 4
Supp Fig2 tif 4.61 MB 3
Supp Fig3 tif 1.44 MB 3

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/97325
タイトル
FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML
著者
Matsukawa, Toshihiro ; Onozawa, Masahiro ; Kondo, Takeshi ; Kanaya, Minoru ; Hidaka, Daisuke ; Ota, Shuichi ; Mori, Akio ; Shigematsu, Akio ; Miyagishima, Takuto ; Kakinoki, Yasutaka ; Hashiguchi, Junichi ; Yamamoto, Satoshi ; Yamamoto, Masayo ; Wakasa, Kentaro ; Takahata, Mutsumi ; Ishihara, Toshimichi ; Haseyama, Yoshihito ; Fujimi, Akihito ; Igarashi, Tetsuya ; Sarashina, Takehiro ; Iyama, Satoshi ; Kobayashi, Ryoji ; Sakai, Hajime ; Fujimoto, Katsuya ; Inamura, Junki ; Kanisawa, Yuji ; Hirabayashi, Shinsuke ; Endo, Tomoyuki ; Hashimoto, Daigo ; Teshima, Takanori
e-Rad_Researcher
20963169
著者名
Matsukawa, Toshihiro
e-Rad_Researcher
70455632
著者名
Onozawa, Masahiro
著者名
Kondo, Takeshi
著者名
Kanaya, Minoru
著者名
Hidaka, Daisuke
著者名
Ota, Shuichi
著者名
Mori, Akio
著者名
Shigematsu, Akio
著者名
Miyagishima, Takuto
著者名
Kakinoki, Yasutaka
著者名
Hashiguchi, Junichi
著者名
Yamamoto, Satoshi
著者名
Yamamoto, Masayo
著者名
Wakasa, Kentaro
著者名
Takahata, Mutsumi
著者名
Ishihara, Toshimichi
著者名
Haseyama, Yoshihito
著者名
Fujimi, Akihito
著者名
Igarashi, Tetsuya
著者名
Sarashina, Takehiro
著者名
Iyama, Satoshi
著者名
Kobayashi, Ryoji
著者名
Sakai, Hajime
著者名
Fujimoto, Katsuya
著者名
Inamura, Junki
著者名
Kanisawa, Yuji
著者名
Hirabayashi, Shinsuke
著者名
Endo, Tomoyuki
著者名
Hashimoto, Daigo
e-Rad_Researcher
40284096
著者名
Teshima, Takanori
言語
英語
キーワード
Acute myeloid leukemia
FLT3-ITD
FLT3 inhibitor
Hematopoietic cell transplantation
発行日
2024-11-30
出版者
Springer
収録物名
Annals of hematology
巻(号)
103(12)
ページ
5333-5340
抄録
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with genetic alterations. The FMS-like tyrosine kinase 3 (FLT3) gene is frequently mutated in adult de novo AML, with two types of mutations: internal tandem duplication (ITD) and point mutations in the tyrosine kinase domain. This study aimed to investigate the impact of FLT3 inhibitors and hematopoietic cell transplantation (HCT) on survival outcomes in patients with FLT3-ITD AML in a real-world setting. We retrospectively analyzed 139 patients with FLT3-ITD-positive AML between 2012 and 2021. The median age was 63 years. In the propensity score-matched cohort, FLT3 inhibitors improved overall survival (OS) compared with patients treated without FLT3 inhibitors (3-year OS: 33.7% vs. 25.8%, p = 0.021). Patients who underwent HCT had superior outcomes to those without HCT (3-year OS: 45.3% vs. 2.2%, p < 0.0001). The combination of FLT3 inhibitors and HCT resulted in the highest OS and relapse-free survival (RFS) rates (3-year OS: 62.4%; 3-year RFS: 44.4%). Disease status before transplantation did not predict the prognosis, but use of FLT3 inhibitors increased survival in patients without complete remission before HCT. These results demonstrate the clinical impact of FLT3 inhibitors on survival outcomes in patients with FLT3-ITD-positive AML, particularly when combined with HCT. FLT3 inhibitors can improve the prognosis of AML with FLT3 mutations, especially in patients who undergo HCT.
資源タイプ
学術雑誌論文
出版タイプ
Accepted Manuscript
権利情報
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00277-024-06125-9
PISSN
0939-5555
EISSN
1432-0584
関連情報 (isVersionOf)
出版社版DOI
https://doi.org/10.1007/s00277-024-06125-9